Due to routine maintenance, access to the Library Open Repository will be interrupted on the morning of Friday 12th February.
We apologise for any inconvenience.

Library Open Repository

Bertilimumab (Cambridge Antibody Technology Group)


Downloads per month over past year

Ding, C and Li, J and Zhang, X (2004) Bertilimumab (Cambridge Antibody Technology Group). Current Opinion in Investigational Drugs, 5 (11). pp. 1213-1219. ISSN 1472-4472

[img] PDF
bertilimumab.pdf | Request a copy
Full text restricted
Available under University of Tasmania Standard License.


Cambridge Antibody Technology (CAT) is developing bertilimumab, an anti-eotaxin-1 monoclonal antibody, for the potential treatment of allergic disorders. By September 2003, CAT had released results from phase I/II trials, and was seeking to outlicense rights for bertilimumab.

Item Type: Article
Journal or Publication Title: Current Opinion in Investigational Drugs
Page Range: pp. 1213-1219
ISSN: 1472-4472
Date Deposited: 01 Apr 2008 03:00
Last Modified: 18 Nov 2014 03:32
Item Statistics: View statistics for this item

Repository Staff Only (login required)

Item Control Page Item Control Page